Is IRTC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Zio volume growth and category leadership, with revenue (ttm) at ~$790M. The bear case rests on regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Analysts covering it are spread from $150.00 to $255.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $150.00, +24.6% from the $120.42 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Zio volume growth and category leadership. The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. The most optimistic analyst target on IRTC is $255.00, +111.8% from the $120.42 price. That figure is only reachable if this thesis works close to its best case.

Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. The company still reports GAAP net losses and trades at a premium revenue multiple, so any volume slowdown, pricing pressure, or launch delay could compress the stock sharply. Competition from larger, better-capitalized players (Philips, Boston Scientific) and the possibility of equity issuance under a shelf registration add further risk. Investors should size positions with the understanding that medtech reimbursement and regulatory outcomes are difficult to predict. The most pessimistic published target is $150.00, +24.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

iRhythm Technologies makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to de

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Zio volume growth and category leadership) stalling in the reported numbers rather than in the narrative, the risk above (regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

iRhythm makes the Zio service, an adhesive patch that continuously records a patient's heart rhythm for up to 14 days. The patch is mailed back and analyzed with AI-assisted algorithms to detect arrhythmias like atrial fibrillation, then a report is sent to the prescribing physician.

iRhythm is adjusted-EBITDA positive and guides to a roughly 12% to 13% adjusted-EBITDA margin for 2026, but it still reports GAAP net losses. Q1 2026 showed a smaller net loss than the prior year alongside about 26% revenue growth, so profitability is improving but not yet consistent on a GAAP basis.

Revenue grew about 26% year over year in Q1 2026 to roughly $199 million, and the company raised full-year 2026 guidance to about $875 million to $885 million, implying roughly 17% to 18% annual growth. Growth is driven by rising Zio prescription volumes and expanding payer coverage.